Minerva discusses roluperidone, targeting negative schizophrenia symptoms
Minerva Neurosciences hosted an investor call to discuss the roluperidone program and its potential to treat negative symptoms within schizophrenia. The event featured guest speakers and an update on clinical research.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed